Search Results
Results found for "Domain Therapeutics"
- Propranolol: A âPick and Rollâ Team Player in Benign Tumors and Cancer Therapies
Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated clear improvement when administered in combination with other therapeutic molecules. In 2008 (and for the first time in the clinic), the therapeutic benefits of the ÎČ-adrenergic receptor
- đ° GPCR Weekly News, May 1 to 7, 2023
Industry News Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023 Neurocrine Biosciences Reports First Quarter 2023 Financial Results Find Therapeutics welcomes critical, we cannot think about one size fits allâ Dr Pina Cardarelli, Chief Scientific Officer, GPCR Therapeutics GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics
- Discover the Hottest GPCR News of the Week: Oct 7-13, 2024!
appreciate the incredible versatility of GPCRs and how small molecules can affect their behavior for therapeutic Learn how to therapeutically exploit GPCRs (Physiologyâs âSwiss Army Knifeâ) vast repertoire of ways Adjust ligand kinetics and tissue disposition for optimal therapeutic activity.
- đ° GPCR Weekly News, June 24 to 30, 2024
Bryan Roth and Brian Krumm for their study on Molecular glues as potential GPCR therapeutics Drs. breast cancer progression by suppressing the MMP8-mediated antitumorigenic effects GPR56: A potential therapeutic via site-selective activation of mTOR GPCR Binders, Drugs, and more Molecular glues as potential GPCR therapeutics
- How Schild Analysis Protects Your Conclusions in GPCR Research
This Week in Premium: Sneak Peek Industry insights: Â Domain CMO; PfizerâMetsera; Novo Nordisk strategy
- đ° GPCR Weekly News, October 23 to 29, 2023
This week's highlight: Congratulations to the GPCR Therapeutics team for their publication on improving Orion's COO, Shared Innovative Insights at LSBC Central European Life Science Investment Conference GPCR Therapeutics Late-Stage Development Progress Parker Moss to Join Exscientia as EVP, Corporate Development Confo Therapeutics
- đ° GPCR Weekly News, July 10 to 16, 2023
GPCRs in Cardiology, Endocrinology, and Taste Clinical, Pathophysiologic, Genetic, and Therapeutic Progress Secures $150 Million in Series B Financing to Advance Pipeline of Novel GPCR-targeted Medicines OMass Therapeutics Directors Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Confo Therapeutics
- đ° GPCR Weekly News, January 29 to February 4, 2024
Xavier Leroy for his new role as CEO of GIO Therapeutics Dr. Molecular mechanism of GPCR spatial organization at the plasma membrane Industry News Launch of GIO Therapeutics , founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation AVROBIO and Tectonic Therapeutic Announce Merger Trevena Inc Elevates Barry
- Inverse Agonists, Lymphatic Fixes & ÎČ-arrestin Tricks
Collaboration is the catalystâletâs redefine whatâs possible in GPCR-driven therapeutics. Â
- đ° GPCR Weekly News, August 7 to 13, 2023
GPCR Symposium on 'GPCRs as Therapeutic Modalities'. Want to share your project in a casual way? npr-38 regulates avoidance and stress-induced sleep in Caenorhabditis elegans Towards the convergent therapeutic Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program Structure Therapeutics
- How to Design GPCR Drugs That Work in Vivo: Strategy, Tools, and Insights
Hereâs what Premium Members accessed this week  across four critical domains: Industry insights:  Neurocrine
- Accelerating GPCR Drug Discovery: What 40 Years of Pharmacology Reveal
Antibodies, Bias, and the Expanding Modality Landscape Antibody therapeutics are now entering spaces once dominated by small molecules.
- Ben Clements on Rescuing Opioids with GPCR Modulators
His work highlights how foundational GPCR science can drive therapeutic innovation.
- đą Early Bird Registration Ends Tomorrow! | Sep 16 - 22, 2024
Discovery on Targetâs 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic INV-347 improves metabolic dysfunction in obese mice Aneesh Karatt Vellatt (CSO & Co-Founder, Maxion Therapeutics ) â BioLeader Interview Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK
- Amylin Receptor Signaling: Three Receptors From One, and How to Profile Each
predict its activity at AMY2 or AMY3, and a molecule's selectivity across the set can shape both its therapeutic Answering those questions cleanly, and early, is what separates a rationally designed amylin therapeutic
- đ° GPCR Weekly News, May 27 to June 2, 2024
tunes mGlu5 receptor function, impacting synaptic transmission Orphan receptor GPR88 as a potential therapeutic the neuropeptide Y4 receptor and its ligand pancreatic polypeptide from a structural, functional, and therapeutic Structural basis for selectivity and antagonism in extracellular GPCR-nanobodies Industry News Structure Therapeutics
- GPR108 is required for gambogic acid inhibiting NF-ÎșB signaling in cancer
Herein, we identified GPR108, a GPCR protein described in innate immune system, is a potential therapeutic Overall, our findings supported GPR108 as a promising therapeutic target of cancer, and provided a small
- Allosteric modulation of GPCRs: From structural insights to in silico drug discovery
orthosteric site), allosteric modulators offer new avenues for the regulation of GPCR function with potential therapeutic today, will facilitate structure-based discovery and development of allosteric modulators as novel therapeutic
- Pepducin-mediated G Protein-Coupled Receptor Signaling in the Cardiovascular System
tools used to manipulate GPCR activity in an orthosteric site-independent manner to compounds with therapeutic development for each receptor, as well as the structural, signaling, pathophysiologic consequences, and therapeutic
- RAB-Symposium - Regulatory Autoantibodies Targeting GPCRs. September 15-16, 2022. LĂŒbeck, Germany...
So far, numerous therapeutics targeting GPCRs have been developed, with a focus on small molecules and been associated with various disease-specific manifestations, highlighting a potential new area for therapeutic
- Predicting GPCR Function: Inside the Carlsson Labâs Modeling Toolbox
Carlssonâs takeaway: AlphaFold is a powerful starting point, but domain expertise and experimental grounding
- đ° GPCR Weekly News, September 25 to October 1, 2023
of traditional Chinese medicine in the treatment of glioblastoma multiforme Industry News Structure Therapeutics Half-Year Financial Results and Exciting Developments at Aelis Farma Ion Channel Drug Developer Maxion Therapeutics Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting
- đ° GPCR Weekly News, September 18 to 24, 2023
GPCR Symposium about 'GPCRs as Therapeutic Modalities' rocked it! recommended by NICE for acute migraines Addex mGlu2 NAM Cognition Program Receives âŹ4 Million Grant Confo Therapeutics Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting
- Building Backwards: Why Top-Down Models Could Revolutionize Pain Research
how inflammation, cognition, and pain circuits overlap , and how GPCRs might serve as more responsive therapeutic
- đ° Breaking Down the Latest GPCR Discoveries: a Weekly Update (Nov 27-Dec 3, 2023)
activity, and structural evaluation Flavonoids as G Protein-coupled Receptors Ligands: New Potential Therapeutic back GPCR agonist after GSK changes course All-rounder among receptors inspires drug research Tectonic Therapeutic Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries Carmot Therapeutics
- Quantifying Receptor Selectivity in Modern Drug Discovery
Another produces a larger shift in ECâ â in one system than another, and we assume weâve found therapeutic In the end, what matters therapeutically is the integrated response.
- First AMA of 2026: GPCR Pharmacology, Biased Signaling & Mechanistic Clarity
The paper explores: Detection and quantification of signaling bias Influence of biased signaling on therapeutic
- Allosteric Effect of Nanobody Binding on Ligand-Specific Active States of the ÎČ2 Adrenergic Receptor
unique allosteric signal transmission mechanisms between the Nb80-binding site and the extracellular domains
- Targeted Drug Design through GPCR Mutagenesis: Insights from ÎČ2AR
activity without directly competing with ligands, potentially reducing side effects and increasing therapeutic the findings of this study have significant implications for drug design, personalised medicine, and therapeutic
- The Hidden Driver of GPCR Drug Success: Why Target Residence Time Matters More Than You Think
cardiometabolic disease, and gain insights into novel approaches in neurodegeneration and antibody therapeutics missed by traditional screening methods, gaining a first-mover advantage in developing more effective therapeutics















